Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy

Fineline Cube Sep 7, 2023

China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...

Policy / Regulatory

CDE’s 2022 Drug Review Report: A Year of Pandemic Response and Regulatory Milestones

Fineline Cube Sep 7, 2023

The Center for Drug Evaluation (CDE) has released its comprehensive 2022 annual drug review report,...

Company Drug

Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist

Fineline Cube Sep 7, 2023

China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical...

Company Deals

Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum

Fineline Cube Sep 7, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73%...

Company Medical Device

Acotec Scientific Holdings Receives Marketing Approvals for Vericor-14 Microcatheter in Japan and Thailand

Fineline Cube Sep 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approvals...

Company Drug

Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B

Fineline Cube Sep 7, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...

Company Drug

MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents

Fineline Cube Sep 6, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant...

Company Deals

Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer

Fineline Cube Sep 6, 2023

China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined...

Company Deals

Abbott to Acquire Insulin Management Firm Bigfoot Biomedical

Fineline Cube Sep 6, 2023

Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...

Policy / Regulatory

Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs

Fineline Cube Sep 6, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have released a...

Company

Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms

Fineline Cube Sep 6, 2023

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...

Policy / Regulatory

Li Li Appointed as New Director of NMPA

Fineline Cube Sep 6, 2023

The State Council has released an announcement regarding appointments and dismissals within the government. Among...

Policy / Regulatory

NHSA Mandates National Standards for Medical Consumables in Basic Medical Insurance

Fineline Cube Sep 6, 2023

The National Healthcare Security Administration (NHSA) has released a notification with a focus on enhancing...

Company Deals

Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases

Fineline Cube Sep 6, 2023

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...

Company Drug

Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA

Fineline Cube Sep 6, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial...

Company Deals

MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications

Fineline Cube Sep 6, 2023

China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements...

Company Drug

Harbin Gloria Pharmaceuticals’ Zimberelimab Receives NMPA Approval for Cervical Cancer Treatment

Fineline Cube Sep 6, 2023

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has announced that it has received market...

Company

Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up

Fineline Cube Sep 6, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management...

Company Drug

Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer

Fineline Cube Sep 5, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), and...

Company Drug

SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis

Fineline Cube Sep 5, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...

Posts pagination

1 … 472 473 474 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.